Sildénafil : interactions médicamenteuses

…following drugs listed in Table 6: Table 6: Drugs Contraindicated with REYATAZ (Information in the table applies to REYATAZ with or without ritonavir, unless otherwise indicated) a See Drug Interactions, Table 16 (7) for parenterally administered midazolam. b See Drug Interactions, Table 16 (7) for sildenafil when dosed as VIAGRA ® for erectile dysfunction. (notice Atazanavir, Contre-indications)

Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended. (notice Clarithromycine, Interactions médicamenteuses)

John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (notice Darunavir, Contre-indications)

John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is contraindicated… (notice Darunavir et cobicistat, Contre-indications)

CONTRAINDICATIONS Administration of SILDENAFIL ORAL FILM to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. (notice Sildénafil, Contre-indications)

CONTRAINDICATIONS Administration of SILDENAFIL ORAL FILM to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. (notice Sildénafil, Contre-indications)

John's wort ( Hypericum perforatum ) Lipid-modifying Agents: lomitapide, lovastatin, simvastatin Phosphodiesterase-5 (PDE-5) Inhibitor: sildenafil when administered as REVATIO ® for the treatment of pulmonary arterial hypertension Sedative/hypnotics: triazolam, orally administered midazolam Coadministration of GENVOYA is contraindicated with drugs that: Are highly… (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Contre-indications)

John’s wort ( Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson… (notice Fosamprénavir, Contre-indications)

Aliskiren Riociguat Sildenafil (for pulmonary hypertension) Tadalafil (for pulmonary hypertension) Not recommended during and 2 weeks after TOLSURA treatment. (notice Itraconazole, Interactions médicamenteuses)

…Inhibitors: lovastatin, simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated… (notice Lopinavir et ritonavir, Contre-indications)

CONTRAINDICATIONS Administration of SILDENAFIL ORAL FILM to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. (notice Sildénafil, Contre-indications)

…ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin receptor 1A agonist/serotonin… (notice Nirmatrelvir et ritonavir, Contre-indications)

Administration with guanylate cyclase (GC) stimulators, such as riociguat. (notice Sildénafil, Contre-indications)

…lovastatin, simvastatin ○ Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide ○ Non-opioid Analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine ○ PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension ○ Sedative/Hypnotics: triazolam, orally administered midazolam • NORVIR is contraindicated… (notice Ritonavir, Contre-indications)

CONTRAINDICATIONS Administration of SILDENAFIL ORAL FILM to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. (notice Sildénafil, Contre-indications)

PDE-5 Inhibitors: Concomitant use is not recommended. (notice Vériciguat, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Alcohol In a drug-drug interaction study of sildenafil 50 mg given with alcohol 0.5 g/kg, in which mean maximum blood alcohol levels of 0.08% was achieved, sildenafil did not potentiate the hypotensive effect of alcohol in healthy volunteers [see Clinical Pharmacology ( 12.2 ) ] . (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

As with other PDE5 inhibitors, SILDENAFIL ORAL FILM has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

PDE-5 inhibitors for erectile dysfunction (ED): Refer to the prescribing information of PDE-5 inhibitors for dose recommendations. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Sildenafil Use with caution Two-fold increase in exposure Monitor for sildenafil toxicity [see Clinical Pharmacology ( 12.3 )]. (notice Ciprofloxacine, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

…ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)] . (notice Déférasirox, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

In addition, the combination of heparin and sildenafil had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Phosphodiesterase type 5 (PDE-5) inhibitors : sildenafil tadalafil vardenafil ↓ sildenafil ↓ N-desmethyl-sildenafil Etravirine and sildenafil can be co-administered without dose adjustments, however, the dose of sildenafil may need to be altered based on clinical effect. (notice Étravirine, Interactions médicamenteuses)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

In addition, the combination of heparin and sildenafil had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (notice Nimodipine, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

However, in vitro studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (notice Phényléphrine, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

…Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl… (notice Rifapentine, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (notice Saproptérine, Interactions médicamenteuses)

Drugs Affecting Nitric Oxide-Mediated Vasorelaxation : Potential for vasorelaxation; monitor blood pressure (e.g., PDE-5 inhibitors). (notice Sépiaptérine, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

As with other PDE5 inhibitors, SILDENAFIL ORAL FILM has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Blood Pressure Decreases Patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure can be sensitive to the actions of vasodilators, including SILDENAFIL ORAL FILM. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

As with other PDE5 inhibitors, SILDENAFIL ORAL FILM has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers. (notice Sildénafil, Mises en garde et précautions)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (notice Sildénafil, Mises en garde et précautions)

CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) increase SILDENAFIL ORAL FILM exposure. (notice Sildénafil, Interactions médicamenteuses)

In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. (notice Sildénafil, Mises en garde et précautions)

In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. (notice Sildénafil, Mises en garde et précautions)

In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. (notice Sildénafil, Mises en garde et précautions)

In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. (notice Sildénafil, Mises en garde et précautions)

No clinically significant drug interactions have been observed between RPV and the following medications: acetaminophen, atorvastatin, chlorzoxazone, ethinyl estradiol, ledipasvir/sofosbuvir, norethindrone, sildenafil, simeprevir, sofosbuvir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, or TDF. (notice Emtricitabine, rilpivirine et ténofovir, Interactions médicamenteuses)

In humans, sildenafil has no effect on bleeding time when taken alone or with aspirin. (notice Sildénafil, Mises en garde et précautions)

…included in Table 6, the interaction between EDURANT and the following drugs was evaluated in clinical studies and no dose adjustment is needed for either drug [see Clinical Pharmacology (12.3) ] : acetaminophen, atorvastatin, chlorzoxazone, cabotegravir, ethinylestradiol, norethindrone, raltegravir, sildenafil, simeprevir and tenofovir disoproxil fumarate. (notice Rilpivirine, Interactions médicamenteuses)